You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 14, 2025

CLINICAL TRIALS PROFILE FOR HYDROCHLOROTHIAZIDE; SPIRONOLACTONE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Hydrochlorothiazide; Spironolactone

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00007592 ↗ Hypertension Screening and Treatment Program Completed US Department of Veterans Affairs 1989-06-01 Hypertension is one of the most common medical problems in the United States and in the VA health care system. It has been well-documented that hypertension can be effectively treated. However, there remain important unresolved clinical questions in the area of antihypertensive treatment. For example, how much is mortality affected by visit compliance, blood pressure control and type of antihypertensive agent? Or, are some regimens associated with more morbidity than others? Or, are there inexpensive regimens that are as effective as more expensive regimens? The amount of data that is available from this demonstration project (currently 6,100 patients) will help address these questions. The answers to these questions should result in better care for veterans with hypertension.
NCT00007592 ↗ Hypertension Screening and Treatment Program Completed VA Office of Research and Development 1989-06-01 Hypertension is one of the most common medical problems in the United States and in the VA health care system. It has been well-documented that hypertension can be effectively treated. However, there remain important unresolved clinical questions in the area of antihypertensive treatment. For example, how much is mortality affected by visit compliance, blood pressure control and type of antihypertensive agent? Or, are some regimens associated with more morbidity than others? Or, are there inexpensive regimens that are as effective as more expensive regimens? The amount of data that is available from this demonstration project (currently 6,100 patients) will help address these questions. The answers to these questions should result in better care for veterans with hypertension.
NCT00224549 ↗ PHARES Study: Management of Resistant Hypertension Completed Assistance Publique - Hôpitaux de Paris Phase 4 2005-04-01 The purpose of this study is to assess the efficacy of two different treatment regimens for treating resistant hypertension previously uncontrolled with at least 3 antihypertensive treatments. The study hypothesis is that these two regimens (one based on increasing diuretics and the other based on increasing renin angiotensin system blockage) may not differ in terms of efficacy.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Hydrochlorothiazide; Spironolactone

Condition Name

Condition Name for Hydrochlorothiazide; Spironolactone
Intervention Trials
Hypertension 4
Metabolic Syndrome X 1
Nephrotic Syndrome 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Hydrochlorothiazide; Spironolactone
Intervention Trials
Hypertension 4
Nephrotic Syndrome 1
Cardiovascular Diseases 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Hydrochlorothiazide; Spironolactone

Trials by Country

Trials by Country for Hydrochlorothiazide; Spironolactone
Location Trials
United States 12
China 1
Mexico 1
Thailand 1
Puerto Rico 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Hydrochlorothiazide; Spironolactone
Location Trials
Tennessee 2
Massachusetts 1
Virginia 1
Pennsylvania 1
Ohio 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Hydrochlorothiazide; Spironolactone

Clinical Trial Phase

Clinical Trial Phase for Hydrochlorothiazide; Spironolactone
Clinical Trial Phase Trials
Phase 4 5
Phase 3 1
N/A 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Hydrochlorothiazide; Spironolactone
Clinical Trial Phase Trials
Completed 4
Recruiting 2
Terminated 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Hydrochlorothiazide; Spironolactone

Sponsor Name

Sponsor Name for Hydrochlorothiazide; Spironolactone
Sponsor Trials
National Heart, Lung, and Blood Institute (NHLBI) 1
National Institutes of Health (NIH) 1
Brigham and Women's Hospital 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Hydrochlorothiazide; Spironolactone
Sponsor Trials
Other 8
NIH 3
U.S. Fed 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Hydrochlorothiazide and Spironolactone: Clinical Trials, Market Analysis, and Projections

Introduction

Hydrochlorothiazide and spironolactone are two widely used medications in the management of various cardiovascular and renal conditions. This article delves into the current clinical trials, market analysis, and future projections for these drugs.

Clinical Trials Update

Hydrochlorothiazide and Spironolactone in Various Conditions

Both hydrochlorothiazide and spironolactone are being extensively studied in clinical trials for their efficacy in treating several conditions. As of the latest data, there are 158 active studies examining the potential of these drugs in providing relief from cirrhosis, edema, and congestive heart failure, among other conditions[1].

  • Cirrhosis and Ascites: Several trials are actively recruiting patients to evaluate the effectiveness of these drugs in managing cirrhosis and associated ascites. These studies are crucial for understanding the optimal dosing and combination therapies that can improve patient outcomes[1].
  • Hypertension: Clinical trials have consistently shown that both hydrochlorothiazide and spironolactone are effective in lowering blood pressure. A double-blind study involving 49 patients with mild-to-moderate essential hypertension demonstrated significant reductions in blood pressure with both drugs, either alone or in combination[3].
  • Nephrotic Syndrome: These drugs are also being studied for their role in managing nephrotic syndrome, a condition characterized by excessive protein loss in the urine. The trials aim to assess their efficacy in reducing edema and improving renal function[1].

Safety and Efficacy

The safety and efficacy profiles of these drugs have been well-established. However, each has unique side effects that need careful monitoring. Hydrochlorothiazide is known to cause hypokalemia (low serum potassium levels), while spironolactone can lead to hyperkalemia (high serum potassium levels) if not closely monitored[4].

Market Analysis

Global Market Trends

The global market for hydrochlorothiazide is expected to grow significantly due to several key factors:

  • Increasing Prevalence of Hypertension: The World Health Organization (WHO) estimates that 1.13 billion people worldwide suffer from hypertension, a number expected to rise to 29% by 2025. This increasing prevalence drives the demand for antihypertensive medications like hydrochlorothiazide[2].
  • Growing Geriatric Population: The rise in the geriatric population, who are more prone to cardiovascular diseases, further boosts the market growth for these drugs[2].
  • Healthcare Expenditure and R&D: Increased healthcare expenditure and robust research and development activities by pharmaceutical companies are also propelling the market forward[2].

Market Size and Projections

The hydrochlorothiazide market is anticipated to experience significant growth from 2021 to 2030. The market is driven by the increasing number of patients suffering from hypertension and other cardiovascular diseases. New product launches and the ongoing development of novel drugs are expected to further flourish the market[2].

Key Impacting Factors

Increase in Hypertension Cases

The rising prevalence of hypertension globally is a major driver for the hydrochlorothiazide market. According to the WHO, hypertension is a leading cause of heart attacks and strokes, making antihypertensive medications essential[2].

Geriatric Population and FDA Approvals

The growing geriatric population and the rise in FDA approvals for new drugs are additional factors contributing to market growth. These approvals often lead to increased adoption and usage of these medications[2].

Side Effects and Monitoring

Despite the benefits, the side effects associated with hydrochlorothiazide, such as hypokalemia, and spironolactone, such as hyperkalemia, are expected to hamper market growth to some extent. Close monitoring and careful patient selection are crucial to mitigate these risks[2][4].

Market Trends

New Product Launches

The launch of novel developed drugs and combination therapies is expected to boost the market. For instance, the combination of hydrochlorothiazide and spironolactone is often used to achieve better control of blood pressure and fluid retention, though this requires careful evaluation due to potential drug interactions[4].

Increasing Awareness for Heart Disease Treatment

Growing awareness for the treatment of heart diseases and the importance of managing hypertension is fueling the market growth. This increased awareness leads to higher demand for effective antihypertensive medications[2].

Expert Insights and Statistics

Effectiveness in Hypertension Management

"Spironolactone is recommended as fourth-line therapy for essential hypertension despite few supporting data for this indication," according to a study published in the American Heart Association journals. This recommendation is based on its effectiveness in lowering blood pressure in patients with and without hyperaldosteronism[5].

Clinical Outcomes

A systematic review from 2012 highlighted that thiazide diuretics like hydrochlorothiazide have favorable outcomes regarding the reduction in mortality and cardiovascular events associated with high blood pressure. Similarly, a meta-analysis from 2004 showed that spironolactone can reverse left ventricular hypertrophy, a common complication of uncontrolled hypertension[4].

Illustrative Statistics

  • Global Hypertension Prevalence: 1.13 billion people worldwide suffer from hypertension, with the prevalence expected to rise to 29% by 2025[2].
  • Clinical Trial Participation: 158 active studies are currently examining the potential of hydrochlorothiazide and spironolactone in various conditions[1].
  • Market Growth: The hydrochlorothiazide market is expected to grow significantly from 2021 to 2030, driven by increasing hypertension cases and healthcare expenditure[2].

Conclusion

Hydrochlorothiazide and spironolactone are crucial medications in the management of hypertension, edema, and other cardiovascular conditions. The ongoing clinical trials and market analysis indicate a strong future for these drugs, driven by increasing demand and advancements in healthcare.

Key Takeaways

  • Clinical Trials: Both drugs are being extensively studied in clinical trials for various conditions, including cirrhosis, edema, and congestive heart failure.
  • Market Growth: The global market for hydrochlorothiazide is expected to grow significantly due to the increasing prevalence of hypertension and other cardiovascular diseases.
  • Safety and Efficacy: Each drug has a unique side effect profile, necessitating careful monitoring and patient selection.
  • Expert Insights: Both drugs are effective in managing hypertension, with spironolactone recommended as fourth-line therapy in certain cases.

FAQs

What conditions are hydrochlorothiazide and spironolactone approved to treat?

Hydrochlorothiazide is approved for treating hypertension, edema due to congestive heart failure, and edema associated with certain kidney disorders. Spironolactone is approved for primary hyperaldosteronism, edematous conditions, essential hypertension, and hypokalemia[4].

How do hydrochlorothiazide and spironolactone work?

Hydrochlorothiazide is a thiazide diuretic that reduces sodium reabsorption in the kidneys, leading to fluid loss. Spironolactone is an aldosterone antagonist that blocks the action of aldosterone, reducing fluid retention and conserving potassium[4].

What are the common side effects of hydrochlorothiazide and spironolactone?

Hydrochlorothiazide can cause hypokalemia (low serum potassium levels), while spironolactone can lead to hyperkalemia (high serum potassium levels) if not closely monitored[4].

Are there any ongoing clinical trials for these drugs?

Yes, there are 158 active studies examining the potential of hydrochlorothiazide and spironolactone in various conditions, including cirrhosis, edema, and congestive heart failure[1].

How is the market for hydrochlorothiazide expected to grow?

The market for hydrochlorothiazide is expected to grow significantly from 2021 to 2030, driven by the increasing prevalence of hypertension, growing geriatric population, and increased healthcare expenditure[2].

Sources

  1. WithPower, "Spironolactone And Hydrochlorothiazide - Clinical Trials".
  2. Allied Market Research, "Hydrochlorothiazide Market Size | Industry Growth, (2021-2030)".
  3. PubMed, "Hydrochlorothiazide and spironolactone in hypertension".
  4. WithPower, "Hydrochlorothiazide vs Spironolactone | Power - Clinical Trials".
  5. American Heart Association Journals, "Effect of Spironolactone on Blood Pressure in Subjects With ...".

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.